BRAF: which options do we have for these patients in second line?

9 / 22

BRAF INHIBITION IN mCRC
Adapted from Van Geel et al. ASCO 2014
1. Corcoran et al. Nature 2012, 2. Prahallad et al. Cancer Discovery 2012
EGFR signaling is inhibited by hyperactive BRAF. In the presence of BRAF inhibitor, EGFR signaling is reactivated either by
the BRAF-MEK pathway or the PI3K-AKT pathway, resulting in cellular proliferation and survival1,2